Sir,
The report by Sinha et al . highlights yet another rare but serious complication secondary to globe perforation (GP) from a peribulbar block (PB). [1] GP from PB has invariably involved injections through the infratemporal or superonasal routes. [2] The infratemporal injection also indirectly contributes to GP when a second injection is done. [3] Due to small amount of free space in the orbit, the globe is displaced medially by the volume of the infratemporal injection done first. This puts the globe in the path of the needle of the second injection done through the medial canthus or superonasal route. [3] Considering that half of the GP go unrecognised at the time of block and its consequences to the individual patient lead to significant visual loss, any reduction in its incidence will be a huge benefit. [2] One easy way to achieve this is to make single medial canthus injection the default option for a PB. This approach was first described by Brahma et al. [4] A maximum of 10 ml of local anaesthetic is injected using a 25G 25-mm needle in the medial canthus [ Figure 1 ]. The choice of local anaesthetic depends on the duration of procedure with 2% lignocaine for short procedures and up to 0.75% bupivacaine or ropivacaine for longer procedures. The injection is extraconal and medial to the medial rectus muscle [ Figure 2 ]. This route is equally effective in comparison to double-injection technique as also with a short 15-mm needle. [5] The indications for this approach are no different from that with infratemporal PB. On the infrequent occasion, the block effect is insufficient; the surgeon can easily do a sub-Tenon space local anaesthetic infiltration. The learning curve for single medial canthus injection PB is short making it an easy technique to learn. It should make GP a very rare if not a 'never event'. It would be ideal if a randomised controlled trial is performed comparing the medial injection technique with infratemporal PB. As the reported incidence of GP in PB is low (2.23/10,000), the number of patients required to detect a significant difference will be very large making a trial of this kind very challenging. [6] Financial support and sponsorship Nil.
